Anti-inflammatory tripeptide for gut and immune support.
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-Melanocyte Stimulating Hormone (α-MSH). It retains the anti-inflammatory properties of the parent hormone while offering a simpler structure, better stability, and potential for direct gut delivery.
The small size of KPV (3 amino acids) gives it a significant advantage for oral delivery: it can survive gastric transit better than larger peptides and reach gut-resident immune cells directly.
KPV activates melanocortin receptors (MC1R, MC3R) in immune cells throughout the gut lining, suppressing the production of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and NF-κB. This cytokine suppression profile is directly relevant to inflammatory bowel conditions where these same cytokines drive intestinal damage.
Direct gut delivery via oral drops means KPV contacts intestinal immune tissue before any systemic absorption — providing local anti-inflammatory signaling exactly where it is needed.
Research in IBD and colitis models documents significant reduction in intestinal inflammation markers, improvement in mucosal barrier integrity, and reduced immune cell infiltration. KPV has shown effectiveness in both Crohn's disease and ulcerative colitis research models.
Oral delivery studies confirm that even with limited systemic bioavailability, orally delivered KPV produces measurable anti-inflammatory effects in gut tissue — supporting the case for oral drops as a delivery-appropriate format for this peptide.
All information is for educational purposes. These statements have not been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease.
Products featuring KPV are launching soon. Browse all formulas →